The role of oxidised regenerated cellulose/collagen in wound repair: Effects in vitro on fibroblast biology and in vivo in a model of compromised healing

International Journal of Biochemistry and Cell Biology

Volumn 34, Issue 12, 2002, Pages 1557-1570

  Hart, Jeffrey ^a   Silcock, Derek ^b   Gunnigle, Stephen ^a   Cullen, Breda ^b   Light, Nicholas D ^b   Watt, Paul W ^b  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^b ETHICON INC   (United States)

Author keywords

Biomaterial; Delayed wound healing; Diabetes; Fibroblast migration proliferation

Indexed keywords

COLLAGEN; OXIDIZED REGENERATED CELLULOSE; OXIDIZED CELLULOSE;

ACCELERATION; ADULT; ANIMAL MODEL; ARTICLE; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DEVICE; DIABETES MELLITUS; DRUG EFFECT; FIBROBLAST; HISTOLOGY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; WOUND; WOUND HEALING; ANIMAL; CELL CULTURE; CELL DIVISION; CELL MOTION; CHRONIC DISEASE; DISEASE MODEL; FEMALE; INJURY; MALE; MOUSE; PATHOLOGY; PHYSIOLOGY; PROTECTIVE CLOTHING; SKIN; TIME;

ADULT; ANIMALS; CELL DIVISION; CELL MOVEMENT; CELLS, CULTURED; CELLULOSE, OXIDIZED; CHRONIC DISEASE; COLLAGEN; DIABETES COMPLICATIONS; DIABETES MELLITUS; DISEASE MODELS, ANIMAL; FEMALE; FIBROBLASTS; HUMANS; MALE; MICE; OCCLUSIVE DRESSINGS; SKIN; TIME FACTORS; WOUND HEALING; WOUNDS AND INJURIES;

EID: 0036887582     PISSN: 13572725     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1357-2725(02)00062-6     Document Type: Article

References (67)

1. J. Hart, Growth factors, in: M. Miller, D. Glover (Eds.), Wound Management Theory and Practice, N.T. Books, London, 2000, pp. 153-169.
2. Sefton M.V., Woodhouse K. Tissue engineering. A. J. Cutan. Med. Surg. 3:1998;18-23.
3. Stocum D.L. Regenerative biology and engineering: strategies for tissue restoration. Wound Rep. Reg. 6:1998;276-290.
4. Herrick S.E., Ireland G.W., Simon D., McCollum C.N., Ferguson M.W. Venous ulcer fibroblasts compared with normal fibroblasts show differences in collagen but not fibronectin production under both normal and hypoxic conditions. J. Invest. Dermatol. 106:1996;187-193.
5. Hasan A., Murata H., Falabella A., Ochoa S., Zhou L., Badiavas E., Falanga V. Dermal fibroblasts from venous ulcers are unresponsive to the action of transforming growth factor-β 1. J. Dermatol. Sci. 16:1997;59-66.
6. Schmid P., Cox D., Bilbe G., McMaster G., Morrison C., Stahelin H., Luscher N., Seiler W. TGF-β and TGF-β type II receptor in human epidermis: differential expression in acute and chronic skin wounds. J. Pathol. 171:1993;191-197.
7. Pierce G.F., Tarpley J.E., Tseng J., Bready J., Chang D., Kenney W.C., Rudolph R., Robson M.C., Vande Berg J., Reid P. Detection of platelet-derived growth factor (PDGF)-AA in actively healing human wounds treated with recombinant PDGF-BB and absence of PDGF in chronic non-healing wounds. J. Clin. Invest. 96:1995;1336-1350.
8. Yager D.R., Chen S.M., Ward S.I., Oluyinka O., Olytoye M.D., Diegelmann R.F., Cohen I.K. Ability of chronic wound fluids to degrade peptide growth factors is associated with increased levels of elastase activity and diminished levels of proteinase inhibitors. Wound Rep. Reg. 5:1997;23-32.
9. Borregaard N., Jensen H.S., Bejerrum O.W. Prevention of tissue damage: inhibition of myeloperoxidase mediated inactivation of α 1-proteianse inhibitor by N-acetyl cysteine, glutathione and methionine. Agents Actions. 22:1987;255-260.
10. Jacob A.K., Hotchkiss R.S., DeMeester S.L., Hiramatsu M., Karl I.E., Swanson P.E., Cobb J.P., Buchman T.G. Endothelial cell apoptosis is accelerated by inorganic iron and heat via an oxygen radical dependent mechanism. Surgery. 122:1997;243-254.
11. M. Symons, J. Gutteridge, Free radicals and Iron: Chemistry, Biology and Medicine, Oxford Science Publications, Oxford, 1998.
12. Kitazawa M., Uwasaki K. Reduction of ultraviolet light-induced oxidative stress by amino acid-based iron-chelators. Biochim. Biophys. Acta. 1473:1999;400-408.
13. Abd-El-Aleem S.A., Ferguson M.W., Appleton I., Kairsingh S., Jude E.B., Jones K., McCollum C.N., Ireland G.W. Expression of nitric oxide synthase isoforms and arginase in normal human skin and chronic leg ulcers. J. Pathol. 191:2000;434-442.
14. Waddington R.J., Moseley R., Embery G. Review: peridontal disease mechanisms. Reactive oxygen species: a potential role in the pathogenesis of peridontal diseases. J. Oral Diseases. 6:2000;138-151.
15. Wysocki A.B., Staiano-Coico L., Grinnell F. Wound fluid from chronic leg ulcers contains elevated levels of metalloproteinases MMP-2 and MMP-9. J. Invest. Dermatol. 101:1993;64-68.
16. Schultz G.S., Mast B.A. Molecular analysis of the environment of healing and chronic wounds: cytokines, proteases and growth factors. Wounds. 10:1998;1F-9F.
17. Harris I.R., Yee K.C., Walters C.E., Cunliffe W.J., Kearney J.N., Wood E.J., Ingham E. Cytokine and protease levels in healing and non-healing chronic venous leg ulcers. Exp. Dermatol. 4:1995;342-349.
18. Rao C.N., Ladin D.A., Liu Y.Y., Chilukuri K., Hou Z.Z., Woodley D. α 1-antitrypsin is degraded and non-functional in chronic wounds but intact and functional in acute wounds: the inhibitor protects fibronectin from degradation by chronic wound fluid enzymes. J. Invest. Dermatol. 105:1995;572-578.
19. Grinnell F., Zhu M. Fibronectin degradation in chronic wounds depends on the relative levels of elastase, α1-proteinase inhibitor, and α2-macroglobulin. J. Invest. Dermatol. 106:1996;335-341.
20. Mast B.A., Schultz G.S. Interactions of cytokines, growth factors and proteases in acute and chronic wounds. Wound Rep. Reg. 4:1996;411-420.
21. Yager D.R., Zhang L.Y., Liang H.X., Diegelmann R.F., Cohen I.K. Wound fluids from human pressure ulcers contain elevated matrix metalloproteinase levels and activity compared to surgical wound fluids. J. Invest. Dermatol. 107:1996;743-748.
22. Wlaschek M., Pees D., Achterberg V., Meyer-Ingold W., Scharfetter-Kochanek K. Protease inhibitors protect growth factor activity in chronic wounds. Br. J. Dermatol. 137:1997;646-647.
23. Porteu F., Brockhus M., Wallach D., Engelmann H., Nathan C.F. Human neutrophil elastase releases a ligand-binding fragment from the 75-kDa tumor necrosis factor (TNF) receptor. Comparison with the proteolytic activity responsible for shedding of TNF receptors from stimulated neutrophils. J. Biol. Chem. 266:1991;18846-18853.
24. Doring G., Frank F., Boudier C., Herbert S., Fleischer B., Bellon G. Cleavage of lymphocyte surface antigens CD2, CD4, and CD8 by polymorphonuclear leukocyte elastase and cathepsin G in patients with cystic fibrosis. J. Immunol. 154:1995;4842-4850.
25. Hamacher J., Sadallah S., Schifferli J.A., Villard J., Nicod L.B. Soluble complement receptor type 1 (CD35) in bronchoalveolar lavage of inflammatory lung diseases. Eur. Resp. J. 11:1998;112-119.
26. R.L. Stilwell, M.G. Marks, L. Safertsein, D.M. Wiseman, in: A.J. Domb, J. Kost, D.M. Wiseman (Eds.), Handbook of Biodegradable Polymers, Harwood Academic Publishers, Amsterdam, 1997, pp. 291-306.
27. Dimitrijevich S.D., Tatarko M., Gracy R.W., Wise G.E., Oakford L.X. In vivo degradation of oxidized, regenerated cellulose. Carbohydr. Res. 198:1990;331-341.
28. Pachence J.M. Collagen-based devices for soft tissue repair. J. Biomed. Mater. Res. 33:1996;35-40.
29. Bailey A.J. The fate of collagen implants in tissue defects. Wound Rep. Reg. 8:2000;5-12.
30. B. Cullen, P.W. Watt, C. Lundqvist, D. Silcock, R.J. Schmidt, D. Bogan, N.D. Light, The role of oxidised regenerated cellulose/collagen in chronic wound repair and its potential mechanism of action. Int. J. Biochem. Cell Biol., 2002, in press.
31. Postlethwaite A.E., Kang A.H. Collagen and collagen peptide-induced chemotaxis of human blood monocytes. J. Exp. Med. 143:1976;1299-1307.
32. Postlethwaite A.E., Seyer J.M., Kang A.H. Chemotactic attraction of human fibroblasts to types I, II and III collagens and collagen derived peptides. Proc. Natl. Acad. Sci. U.S.A. 75:1978;871-875.
33. Lyon M., Deakin J.A., Rahmoune H., Fernig D.G., Nakamura T., Gallagher J.T. Hepatocyte growth factor/scatter factor binds with high affinity to dermatan sulfate. J. Biol. Chem. 273:1998;271-278.
34. Sattar A., Rooney P., Kumar S., Pye D., West D.C., Scott I., Ledger P. Application of angiogenic oligosaccharides of hyaluronan increases blood vessel numbers in rat skin. J. Invest. Dermatol. 103:1994;576-579.
35. Stringer S.E., Gallagher J.T. Heparan sulphate. Int. J. Biochem. Cell Biol. 29:1997;709-714.
36. Greenhalgh D.G., Sprugel K.H., Murray M.J., Ross R. PDGF and FGF stimulate wound healing in the genetically diabetic mouse. Am. J. Pathol. 136:1990;1235-1246.
37. Brown D.L., Breeden M.P., Greenhalgh D.G. PDGF and TGF-α act synergistically to improve wound healing in the genetically diabetic mouse. J. Surg. Res. 56:1994;562-570.
38. Doxey D.L., Ng M.C., Dill R.E., Iacopino A.M. Platelet-derived growth factor levels in wounds of diabetic rats. Life Sci. 57:1995;1111-1123.
39. Bitar M.S., Labbad Z.N. Transforming growth factor-β and insulin-like growth factor-I in relation to diabetes-induced impairment of wound healing. J. Surg. Res. 6:1996;113-119.
40. Beer H.D., Longaker M.T., Werner S. Reduced expression of PDGF and PDGF receptors during impaired wound healing. J. Invest. Dermatol. 109:1997;132-138.
41. Brown D.L., Kao W.W., Greenhalgh D.G. Apoptosis down-regulates inflammation under the advancing epithelial wound edge: delayed patterns in diabetes and improvement with topical growth factors. Surgery. 121:1997;372-380.
42. Matuszewska B., Keogan M., Fisher D.M., Soper K.A., Hoe C.M., Huber A.C., Bondi J.V. Acidic fibroblast growth factor: evaluation of topical formulations in a diabetic mouse wound healing model. Pharm. Res. 11:1994;65-71.
43. Okumura M., Okuda T., Nakamura T., Yajima M. Effect of basic fibroblast growth factor on wound healing in healing-impaired animal models. Arzneimittel-Forschung. 46:1996;547-551.
44. Hennessey P.J., Black C.T., Andrassy R.J. EGF increases short-term type I collagen accumulation during wound healing in diabetic rats. J. Pediatr. Surg. 25:1990;893-897.
45. Fahey T.J., Sadaty A., Jones W.G., Barber A., Smoller B., Shires G.T. Diabetes impairs the late inflammatory response to wound healing. J. Surg. Res. 50:1991;308-313.
46. Werner S., Breeden M., Hubner G., Greenhalgh D.G., Longaker M.T. Induction of keratinocyte growth factor expression is reduced and delayed during wound healing in the genetically diabetic mouse. J. Invest. Dermatol. 103:1994;469-473.
47. A.F. Brown, Neutrophil and monocyte behaviour in three-dimensional collagen matrices, Scan Electron. Microsc. II (1984) 747-754.
48. Kuntz R.M., Saltzman W.M. Neutrophil motility in extracellular matrix gels: mesh size and adhesion affect speed of migration. Biophys. J. 72:1997;1472-1480.
49. Malone J.D., Richards M., Jeffrey J.J. Recruitment of peripheral mononuclear cells by mammalian collagenase digests of type I collagen. Matrix. 11:1991;289-295.
50. Laskin D.L., Kimura T., Sakakibara S., Riley D.J., Berg R.A. Chemotactic activity of collagen-like polypeptides for human peripheral blood neutrophils. J. Leuk. Biol. 39:1986;255-266.
51. Laskin D.L., Soltys R.A., Berg R.A., Riley D.J. Activation of alveolar macrophages by native and synthetic collagen-like polypeptides. Am. J. Resp. Cell. Mol. Biol. 10:1994;58-64.
52. Pierce A.M., Wiebkin O.W., Wilson D.F. Surgicel: its fate following implantation. J. Oral. Pathol. 13:1982;661-670.
53. Albini A., Adelmann-Grill B.C. Collagenolytic cleavage products of collagen type I as chemoattractants for human dermal fibroblasts. Eur. J. Cell. Biol. 36:1985;104-107.
54. Cawston T.E., Weaver L., Coughlan R.J., Kyle M.V., Hazleman B.L. Synovial fluids from infected joints contain active metalloproteinases and no inhibitory activity. Br. J. Rheumatol. 28:1989;386-392.
55. Grinnell F., Ho C.H., Wysocki A. Degradation of fibronectin and vitronectin in chronic wound fluid: analysis by cell blotting, immunoblotting, and cell adhesion assays. J. Invest. Dermatol. 98:1992;410-416.
56. Bullen E.C., Longaker M.T., Updike D.L., Benton R., Ladin D., Hou Z., Howard E.W. Tissue inhibitor of metalloproteinases-1 is decreased and activated gelatinases are increased in chronic wounds. J. Invest. Dermatol. 104:1995;236-240.
57. Weckroth M., Vaheri A., Lauharanta J., Sorsa T., Konttinen Y.T. Matrix metallo-proteinases, gelatinase and collagenase, in chronic leg ulcers. J. Invest. Dermatol. 106:1996;1119-1124.
58. Barone E.J., Yager D.R., Pozez A.L., Olutoye O.O., Crossland M.C., Diegelmann R.F., Cohen I.K. Interleukin-1α and collagenase activity are elevated in chronic wounds. Plast. Reconstr. Surg. 102:1998;1023-1027.
59. Saarialho-Kere U.K. Patterns of matrix metalloproteinase and TIMP expression in chronic ulcers. Arch. Dermatol. Res. 290:1998;S47-54.
60. Nwomeh B.C., Liang H.X., Cohen I.K., Yager D.R. MMP-8 is the predominant collagenase in healing wounds and non-healing ulcers. J. Surg. Res. 81:1999;189-195.
61. Trengove N.J., Stacey M.C., MacAuley S., Bennett N., Gibson J., Burslem F., Murphy G., Schultz G. Analysis of the acute and chronic wound environments: the role of proteases and their inhibitors. Wound Rep. Reg. 7:1999;442-452.
62. Palolahti M., Lauharanta L., Stephens R.W., Kuusela P., Vaheri A. Proteolytic activity in leg ulcers. Exp. Dermatol. 2:1993;29-37.
63. Stacey M.C., Burnand K.G., Mahmoud-Alexandroni M., Gaffney P.J., Bhogal B.S. Tissue and urokinase plasminogen activators in the environs of venous and ischaemic leg ulcers. Br. J. Surg. 80:1993;596-599.
64. Rogers A.A., Burnett S., Moore J.C., Shakespeare P.G., Chen W.Y.J. Involvement of proteolytic enzymes plasminogen activators and matrix metalloproteinases in the pathophysiology of pressure ulcers. Wound Rep. Reg. 3:1995;273-283.
65. Herrick S., Ashcroft G., Ireland G., Horan M., McCollum C., Ferguson M. Up-regulation of elastase in acute wounds of healthy aged humans and chronic venous leg ulcers are associated with matrix degradation. Lab. Invest. 77:1997;281-288.
66. Lauer G., Sollberg S., Cole M., Flamme I., Stürzebecher J., Mann K., Krieg T., Eming S.A. Expression and proteolysis of vascular endothelial growth factor is increased in chronic wounds. J. Invest. Dermatol. 115:2000;12-18.
67. Falanga V., Eaglstein W., Bucalo B., Katz M., Harris B., Carson P. Topical use of human recombinant epidermal growth factor (h-EGF) in venous ulcers. J. Dermol. Surg. Oncol. 18:1992;604-606.